Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

141
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
141
Cancer Survival Analysis01:21

Cancer Survival Analysis

303
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
303
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

90
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
90

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Platinum Rechallenge in Platinum-Resistant Ovarian Cancer: Clinical Outcomes and the Impact of BRCA Status.

Cancers·2026
Same author

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

NPJ precision oncology·2026
Same author

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Constitutional <i>BRCA1</i> Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

JCO precision oncology·2026
Same author

Quality and safety of research biopsies in oncology clinical trials.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Related Experiment Video

Updated: May 13, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.5K

Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined

Dominik Denschlag1, Florian Heitz2, Jacobus Pfisterer3

  • 1OB/GYN, Hochtaunus Kliniken gGmbH, Bad Homburg vor der Hohe, Germany.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|April 14, 2025
PubMed
Summary

Co-medication with metformin or statins did not impact survival in ovarian cancer patients. However, beta blocker use was linked to worse survival, though the reason remains unclear.

Keywords:
Ovarian Cancer

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.5K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.8K

Related Experiment Videos

Last Updated: May 13, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.5K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.5K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.8K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Ovarian cancer patients often have comorbidities requiring co-medications.
  • The impact of common co-medications like metformin, statins, and beta blockers on ovarian cancer survival is not well-established.

Purpose of the Study:

  • To investigate the association between co-medication with metformin, statins, or beta blockers and survival outcomes in primary ovarian cancer patients.

Main Methods:

  • Pooled data from four clinical trials (AGO-OVAR 11, 12, 15, 16) involving 2857 ovarian cancer patients.
  • Patients were categorized as 'ever users' or 'never users' of specific co-medications.
  • Multivariate Cox regression analyses adjusted for confounders were used to assess survival impacts.

Main Results:

  • Co-medication with metformin (n=100) or statins (n=226) showed no significant impact on progression-free survival (PFS) or overall survival (OS).
  • Co-medication with selective beta blockers (n=391) was significantly associated with a higher risk of recurrence and death (PFS HR 1.22, OS HR 1.25).
  • Ever users of co-medications were older, more obese, and had higher comorbidity scores.

Conclusions:

  • Metformin and statin co-medication do not appear to significantly affect survival in primary ovarian cancer.
  • Selective beta blocker use is associated with worse survival outcomes in ovarian cancer patients.
  • Further research is needed to determine if the observed association with beta blockers is due to the drug's effect on tumor biology or underlying patient conditions.